Tumor PD-L1 expression, quantified by immunohistochemistry on tumor cells or infiltrating immunecells, serves as a provisional companion diagnostic for PD-1/PD-L1 inhibitors; however, assay variability and dynamic regulation ofPD-L1 limit its predictive precision. Here, CD274 is linked to neoplasm.